

NOTICE OF CHANGE IN CORPORATE STRUCTURE

Pursuant to Section 4.9 of National Instrument 51-102 *Continuous Disclosure Requirements*

1. Names of the parties to the transaction.

NuGen Medical Devices Inc., formerly BuzBuz Capital Corp. (the "**Company**")
EPG Global Ltd., formerly Inolife R&D Inc. ("**Inolife**")
13397840 Canada Inc. ("**BuzBuz Subco**")

2. Description of the transaction.

On October 19, 2021, the Company closed its previously announced business combination with Inolife (the "Transaction"). The Company acquired all of the issued and outstanding common shares in the capital of Inolife by way of a "three-cornered" statutory amalgamation, pursuant to which a wholly-owned subsidiary of the Company amalgamated with Inolife and each Inolife shareholder received one post-consolidation common share in the capital of the Company for each post-consolidation Inolife common share held. As part of the transaction, the Company consolidated its common shares on the basis of two pre-consolidation common shares to one post-consolidation common share (each post-consolidation common share, a "Common Share") and changed its name from BuzBuz Capital Corp. to NuGen Medical Devices Inc. and the directors and management of Inolife became the directors and management of the Company.

Following the completion of the transaction, Inolife (now renamed EPG Global Ltd.) is now a wholly-owned subsidiary of the Company and the Company meets the listing requirements for a Tier 2 life sciences issuer on the TSX Venture Exchange. The Company will continue the business of Inolife, which is an emerging specialty medical device company focused on developing and commercializing novel needle-free drug delivery technologies.

The Transaction constitutes the Company's "Qualifying Transaction" within the meaning of the TSX Venture Exchange policies.

3. Effective date of the transaction.

October 19, 2021.

4. Name of each party, if any, that ceased to be a reporting issuer after the transaction and of each continuing entity.

The Company continues as a reporting issuer in British Columbia, Alberta, Saskatchewan and Ontario as NuGen Medical Devices Inc.

5. Date of the reporting issuer's first financial year-end after the transaction if paragraph (a) or subparagraph (b)(ii) applies

December 31, 2021

6. Periods, including comparative periods, if any, of the interim financial reports and the annual financial statements required to be filed for the company's first financial year after the transaction, if paragraph (a) or subparagraph (b)(ii) applies.

The Company will be required to file annual financial statements for the year ending December 31, 2021, including comparative information for the year ending December 31, 2020.

Inolife will be required to file reverse takeover acquirer interim financial statements for the period ending September 30, 2021, including comparative information for the period ending September 30, 2020.

7. Documents filed that describe the transaction and where those documents can be found in electronic format.

The following documents describing the Transaction were filed on SEDAR and are available under the Company's issuer profile at www.sedar.com:

- Business Combination Agreement dated October 1, 2020 between the Company and Inolife;
- Non-Offering Prospectus dated September 29, 2021
- News releases dated August 7, 2020, October 2, 2020, November 3, 2020, December 24, 2020, December 30, 2020, September 30, 2021 and October 19, 2021; and
- Material change reports dated October 5, 2020, September 30, 2021 and October 20, 2021.

DATED October 29, 2021.